Juvenescence and the Buck Institute launch Selah Therapeutics, targeting heart disease

Juvenescence Limited (“Juvenescence”) and the Buck Institute for Research on Aging (the “Buck) announce a new joint venture with the formation of Selah Therapeutics Limited (“Selah”). The company will focus on developing first-in-class novel ketone-based therapies for chronic diseases of aging of which our first therapeutic focus is heart disease with secondary interests in neurological diseases.

Selah Therapeutics is based on research conducted on ketones in the labs of Dr. Eric Verdin, MD, Dr. John Newman, MD, PhD , and Brianna Stubbs, PhD at the Buck around energetics and intracellular signaling pathways, and the ketone platform that Juvenescence has built around its JuvLife Division’s product Metabolic Switch®.

“Selah’s mission is focused on developing and commercializing products that have strong scientific evidence that will transform the treatment to patients with heart and neurological diseases. We believe that the deep expertise in the science of ketones from both Juvenescence and the Buck, along with an extensive library of novel and proprietary compounds identified by Drs. Verdin, Newman and Stubbs that have unique qualities will provide improved well-being to the patient as a prescription therapeutic for heart disease,” said Jeff Madwed, PhD , Executive Director of Juvenescence’s JuvTherapeutics Division.

“We are delighted to be building on our existing relationship with Juvenescence in this new venture,” said Dr. Eric Verdin, MD, Buck President and CEO. “This is an area of great unmet need and we are hopeful that we will be able to bring an important new therapeutic option to cardiovascular patients”.